Becton Dickinson and Company
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Becton Dickinson and Company (BDX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Medical | $7.64B 47.5% | $8.36B 43.7% · +9.5% | $8.84B 46.9% · +5.7% | $9.50B 49.1% · +7.5% | $10.07B 49.8% · +6.0% | $11.46B 52.5% · +13.7% |
| Interventional | $3.76B 23.4% | $4.24B 22.2% · +12.7% | $4.46B 23.7% · +5.3% | $4.74B 24.4% · +6.1% | $4.98B 24.6% · +5.2% | $5.22B 23.9% · +4.8% |
| Life Sciences | $4.68B 29.1% | $6.53B 34.1% · +39.7% | $5.56B 29.5% · -14.8% | $5.13B 26.5% · -7.7% | $5.19B 25.6% · +1.1% | $5.17B 23.7% · -0.5% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Medical | – | – | – | $3.35B 35.3% | $3.58B 35.6% | $4.14B 36.1% |
| Interventional | – | – | – | $1.94B 40.9% | $2.12B 42.5% | $2.25B 43.2% |
| Life Sciences | – | – | – | $1.60B 31.2% | $1.62B 31.1% | $1.64B 31.8% |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.